Low-Dose Maintenance Intravenous Iron Therapy Can Prevent Anemia in Children with End-Stage Renal Disease Undergoing Chronic Hemodialysis
Table 1
Comparative baseline characteristics of the treatment group versus the comparison group.
Characteristics
Treatment group (n = 21)
Comparison group (n = 20)
value
Age, mean, 95% CI
13.5 (12–15.1)
14.7 (13.8–15.7)
0.17
Male, n (%)
15 (71.4%)
15 (75%)
0.8
Primary disease, n (%)
Urological abnormalities
3 (14.3%)
4 (20%)
Glomerulopathy
8 (38.1%)
8 (40%)
Kidney hypoplasia and dysplasia
10 (47.6%)
8 (40%)
Nutritional status
Well-nourished
8 (38.1%)
16 (76.2%)
Malnourished
13 (61.9%)
4 (23.8%)
Hemodialysis access
Tunneled catheter
19 (90.5%)
18 (90%)
Arteriovenous fistula
2 (9.5)
2 (10%)
ESA dosage (IU/kg/week), mean, 95% CI
331.7 (256.4–407.1)
325.7 (241.1–410.3)
0.9
Hb (g/L), mean, 95% CI
125 (121–129)
131 (123–140)
0.17
MCV (fL), mean, 95% CI
87.5 (85.6–89.3)
86.2 (82.4–90.1)
0.54
MCH (pg/cell), mean, 95% CI
1.78 (28.1–29.4)
28.5 (27.2–29.9)
0.71
MCHC (g/L), mean, 95% CI
331 (325–336)
331 (323–338)
0.99
Absolute reticulocyte count (×109/L), mean, 95% CI
72.9 (55.7–90)
78.1 (62.5–93.8)
0.64
Relative reticulocyte count, mean, 95% CI
0.02 (0.016–0.024)
0.019 (0.015–0.023)
0.79
SI (µmol/L), mean, 95% CI
11.6 (9.5–13.7)
15.7 (12.5–18.9)
0.03
TIBC (µmol/L), mean, 95% CI
35.6 (33.4–37.9)
37.3 (32.7–41.9)
0.51
TSAT (%), mean, 95% CI
34 (26.9–41.2)
43.4 (33.6–53.2)
0.11
Ferritin (µg/L), mean, 95% CI
1074 (722.4–1425.6)
1799.3 (828.7–2769.9)
0.15
Dialysis vintage (days) median, range
90 (5–1014)
202 (28–927)
0.73
CI = confidence interval, ESA = erythropoiesis-stimulating agent, Hb = hemoglobin, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration, SI = serum iron, TIBC = total iron binding capacity, and TSAT = transferrin saturation.
